Data from ISENTRESS®, Merck's HIV Integrase Inhibitor, in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections
ISENTRESS is the first integrase inhibitor approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of viral replication with HIV-1 strains resistant to multiple antiretroviral agents.
...
Also, the study showed that ISENTRESS did not demonstrate non-inferior virologic efficacy at maintaining viral load suppression. As a result of the viral load findings in these trials, Merck discontinued these two studies.
